Compile Data Set for Download or QSAR
Report error Found 48 Enz. Inhib. hit(s) with all data for entry = 11225
TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473569(US10844057, Example 12 | US10947229, Example 5 | U...)
Affinity DataKi:  0.0250nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473567(US10844057, Example 10 | US10947229, Example 3 | U...)
Affinity DataKi:  0.0250nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473564(US10844057, Example 7 | US10947229, Example 1 | US...)
Affinity DataKi:  0.0320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473569(US10844057, Example 12 | US10947229, Example 5 | U...)
Affinity DataKi:  0.0320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473570(US10844057, Example 13 | US10947229, Example 6 | U...)
Affinity DataKi:  0.0320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473567(US10844057, Example 10 | US10947229, Example 3 | U...)
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473570(US10844057, Example 13 | US10947229, Example 6 | U...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473569(US10844057, Example 12 | US10947229, Example 5 | U...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473567(US10844057, Example 10 | US10947229, Example 3 | U...)
Affinity DataKi:  0.0630nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473564(US10844057, Example 7 | US10947229, Example 1 | US...)
Affinity DataKi:  0.0630nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.0630nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473564(US10844057, Example 7 | US10947229, Example 1 | US...)
Affinity DataKi:  0.0630nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0790nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0790nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0790nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.126nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473570(US10844057, Example 13 | US10947229, Example 6 | U...)
Affinity DataKi:  0.158nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.316nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.316nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.316nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.398nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.398nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.398nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.398nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.501nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.631nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473567(US10844057, Example 10 | US10947229, Example 3 | U...)
Affinity DataKi:  0.794nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.794nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473564(US10844057, Example 7 | US10947229, Example 1 | US...)
Affinity DataKi:  0.794nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473569(US10844057, Example 12 | US10947229, Example 5 | U...)
Affinity DataKi:  1nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM473570(US10844057, Example 13 | US10947229, Example 6 | U...)
Affinity DataKi:  1nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent